glutamic acid has been researched along with Dyskinesia, Medication-Induced in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 17 (36.17) | 29.6817 |
| 2010's | 22 (46.81) | 24.3611 |
| 2020's | 5 (10.64) | 2.80 |
| Authors | Studies |
|---|---|
| Frouni, I; Huot, P | 1 |
| Aguirre-Pérez, A; Alfaro-Rodriguez, A; Arias-Montaño, JA; Avila-Luna, A; Bueno-Nava, A; Gálvez-Rosas, A; Hidalgo-Bravo, A; Ríos, C | 1 |
| Liu, M; Tuo, J; Xu, Z; Yu, C; Zhang, F; Zhang, J; Zhang, L | 1 |
| Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X | 1 |
| Brugnoli, A; Morari, M; Pisanò, CA | 1 |
| Gardoni, F; Mellone, M | 1 |
| Ivanova, SA; Loonen, AJ | 1 |
| Auberson, YP; Budri, M; Calcagno, M; Dekundy, A; Mabrouk, OS; Mela, F; Morari, M; Parsons, CG; Viaro, R | 1 |
| Amalric, M | 1 |
| Alen, F; Bilbao, A; Blanco, E; Luque-Rojas, MJ; Palomino, A; Pavón, FJ; Rivera, P; Rodríguez de Fonseca, F; Serrano, A; Suárez, J; Vida, M | 1 |
| Arcuri, L; Brugnoli, A; Mercatelli, D; Morari, M; Paolone, G | 1 |
| Brugnoli, A; Morari, M; Napolitano, F; Usiello, A | 1 |
| Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Asensio, MJ; García-Sanz, P; Herranz, AS; Moratalla, R; Solís, O | 1 |
| Bagga, P; Crescenzi, R; Detre, JA; Greenberg, J; Hariharan, H; Krishnamoorthy, G; Nanga, RP; Reddy, D; Reddy, R; Verma, G | 1 |
| Cao, X; Chen, G; Han, C; Ma, K; Nie, S; Papa, SM; Wang, T; Xiong, N; Xu, Y; Zhang, Z | 1 |
| Danysz, W; Dekundy, A; Gravius, A; Morè, L; Nagel, J; Pietraszek, M | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Mela, F; Recchia, A; Rylander, D | 1 |
| Mabrouk, OS; Marti, M; Morari, M | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hornykiewicz, O; Johns, DR; Morissette, M; Ouattara, B; Rajput, A; Rajput, AH; Vranesic, I | 1 |
| Bishop, C; Button, T; Dupre, KB; Eskow Jaunarajs, KL; Ostock, CY; Savage, LM; Wolf, W | 1 |
| Austin, PJ; Betts, MJ; Broadstock, M; Duty, S | 1 |
| Brotchie, JM; Huot, P | 1 |
| Bido, S; Cenci, MA; Marti, M; Mela, F; Morari, M | 1 |
| Cenci, MA; Sgambato-Faure, V | 1 |
| Ikarashi, Y; Kanno, H; Kase, Y; Sekiguchi, K; Yamaguchi, T | 1 |
| Bezard, E; Brambilla, R; Calabresi, P; Fasano, S; Guerrini, R; Li, Q; Marti, M; Morari, M; Morella, I; Rodi, D; Simonato, M; Tozzi, A | 1 |
| Gerhardt, GA; Lundblad, M; Nevalainen, N; Strömberg, I | 1 |
| Chase, TN; Oh, JD | 1 |
| Blanchet, PJ; Chase, TN; Metman, LV | 1 |
| Bédard, PJ; Bélanger, N; Darré, A; Grégoire, L; Hadj Tahar, A; Meltzer, L | 1 |
| Bianchi, C; Calò, G; Guerrini, R; Marti, M; Mela, F; Morari, M | 1 |
| Alves, A; Burger, ME; Callegari, L; Fachineto, R; Rocha, JB | 1 |
| Aksu, M; Bara-Jimenez, W; Chase, TN; Dimitrova, TD; Sherzai, A | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Marti, M; Mela, F; Morari, M | 1 |
| Pilowsky, LS; Stone, JM | 1 |
| Gardoni, F | 1 |
| Andrén, PE; Gunne, LM | 1 |
| Allen, C; Andreassen, OA; Jørgensen, HA; Meshul, CK | 1 |
| Rascol, O | 1 |
| Bernardi, G; Calabresi, P; Centonze, D | 1 |
| Baas, H | 1 |
| Kulkarni, SK; Naidu, PS | 1 |
| Andreassen, OA; Jørgensen, HA; Meshul, CK; Moore, C | 1 |
| Djaldetti, R; Melamed, E; Merims, D; Sherki, Y; Ziv, I | 1 |
12 review(s) available for glutamic acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Glutamate modulation for the treatment of levodopa induced dyskinesia: a brief review of the drugs tested in the clinic.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; N-Methylaspartate; Parkinson Disease | 2022 |
Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation.
Topics: Aged; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Middle Aged; N-Methylaspartate; Neuroinflammatory Diseases; Parkinson Disease; Quality of Life; Receptors, N-Methyl-D-Aspartate | 2023 |
New insights into the mechanism of drug-induced dyskinesia.
Topics: Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Humans; Levodopa; Neural Pathways; Thalamus | 2013 |
Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Metabotropic Glutamate | 2015 |
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Dopamine; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Parkinson Disease; Receptors, AMPA; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2012 |
Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Motor Activity; Parkinson Disease; Receptors, Cell Surface | 2002 |
Renaissance of amantadine in the treatment of Parkinson's disease.
Topics: Amantadine; Animals; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2003 |
Novel targets for drugs in schizophrenia.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Neurotransmitter Agents; Receptors, Cholinergic; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia | 2007 |
MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Chronic Disease; Disks Large Homolog 4 Protein; Dyskinesia, Drug-Induced; Glutamic Acid; Guanylate Kinases; Humans; Huntington Disease; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Pain; Protein Subunits; Receptors, N-Methyl-D-Aspartate; Stroke; Synapses | 2008 |
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
Topics: Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Narcotics; Norepinephrine; Parkinson Disease; Receptors, Dopamine; Serotonin | 1999 |
Electrophysiology of dopamine in normal and denervated striatal neurons.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electrophysiology; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons; Parkinson Disease | 2000 |
Dyskinesia in Parkinson's disease. Pathophysiology and clinical risk factors.
Topics: Corpus Striatum; Drug Therapy; Dyskinesia, Drug-Induced; Glutamic Acid; Humans; Levodopa; Neural Pathways; Neuropeptides; Parkinson Disease; Receptors, Dopamine; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Risk Factors | 2000 |
1 trial(s) available for glutamic acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Glutamate release inhibition ineffective in levodopa-induced motor complications.
Topics: Aged; Antiparkinson Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Riluzole; Treatment Outcome | 2006 |
34 other study(ies) available for glutamic acid and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Chronic H
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Rats; RNA, Messenger | 2023 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics | 2020 |
Glutamatergic mechanisms in L-DOPA-induced dyskinesia and therapeutic implications.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Levodopa; Neurons; Receptors, Glutamate | 2018 |
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Phenols; Piperidines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2013 |
Cocaine-induced behavioral sensitization is associated with changes in the expression of endocannabinoid and glutamatergic signaling systems in the mouse prefrontal cortex.
Topics: Amidohydrolases; Animals; Cocaine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Endocannabinoids; Glutamic Acid; Glutaminase; Lipoprotein Lipase; Male; Mice, Inbred C57BL; Monoacylglycerol Lipases; Phospholipase D; Prefrontal Cortex; Receptor, Cannabinoid, CB1; Receptors, Glutamate; RNA, Messenger | 2014 |
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamic Acid; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Oxidopamine; Parkinson Disease; Piperazines; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors | 2015 |
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Glutamic Acid; GTP-Binding Proteins; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Multiprotein Complexes; Neurons; Neuroprotective Agents; Sirolimus; Substantia Nigra; TOR Serine-Threonine Kinases | 2016 |
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; gamma-Aminobutyric Acid; Glutamic Acid; Glycine; Levodopa; Mice; Oxidopamine; Rotarod Performance Test; Taurine; Tyrosine | 2016 |
Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Brain Chemistry; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Gliosis; Glutamic Acid; Hand Strength; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neostriatum; Tyrosine 3-Monooxygenase; Vesicular Glutamate Transport Protein 1 | 2016 |
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Calcineurin; Calcium Ionophores; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glutamic Acid; Ionomycin; Levodopa; Male; MAP Kinase Signaling System; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2017 |
Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Anxiety Disorders; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Glutamic Acid; Learning Disabilities; Levodopa; Male; Maze Learning; Memory Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Synaptic Transmission; Thiazoles | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Motor Activity; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Synaptic Transmission | 2009 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Narcotic Antagonists; Neuropharmacology; Nociceptin; Nociceptin Receptor; Opioid Peptides; Parkinsonian Disorders; Piperidines; Receptors, Opioid; Substantia Nigra; Synaptic Transmission | 2010 |
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cohort Studies; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Humans; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Up-Regulation | 2011 |
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Benzazepines; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists | 2011 |
Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.
Topics: Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Reserpine; Substantia Nigra | 2012 |
5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Glutamic Acid; Male; Parkinson Disease, Secondary; Receptor, Serotonin, 5-HT1A | 2011 |
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels.
Topics: Animals; Benzazepines; Corpus Striatum; Dopamine Antagonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Raclopride; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Substantia Nigra | 2012 |
Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Glutamic Acid; Haloperidol; Humans; Male; Mastication; Movement; Rats; Rats, Wistar; Treatment Outcome | 2012 |
Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Autoradiography; Behavior, Animal; Dyskinesia, Drug-Induced; Electrophysiological Phenomena; Excitatory Postsynaptic Potentials; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Microinjections; Nociceptin; Opioid Peptides; Oxidopamine; Postural Balance; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2012 |
Striatal glutamate release in L-DOPA-induced dyskinetic animals.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Injections, Intraventricular; Levodopa; Potassium; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin Receptor Agonists; Signal Transduction | 2013 |
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Topics: Animals; Benzoxazoles; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Glutamic Acid; Levodopa; Macaca fascicularis; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartate; Treatment Outcome | 2004 |
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
Topics: Animals; Dopamine Antagonists; Dyskinesia, Drug-Induced; Glutamic Acid; Haloperidol; Male; Microdialysis; Nociceptin; Opioid Peptides; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2004 |
Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Topics: Animals; Antipsychotic Agents; Brain; Disease Models, Animal; Drug Administration Schedule; Dyskinesia, Drug-Induced; Glutamic Acid; Haloperidol; Male; Mastication; Rats; Rats, Wistar; Reserpine; Synaptosomes; Tongue | 2005 |
Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Neural Inhibition; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Substantia Nigra; Synaptic Transmission | 2007 |
An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia.
Topics: Animals; Brain Chemistry; Cebus; Disease Models, Animal; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamates; Glutamic Acid; Parkinson Disease | 1993 |
Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Caudate Nucleus; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Haloperidol; Rats; Rats, Sprague-Dawley; Synapses | 1996 |
Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide.
Topics: Animals; Antipsychotic Agents; Calcium; Dyskinesia, Drug-Induced; Glutamic Acid; Haloperidol; Male; Mastication; N-Methylaspartate; Nitric Oxide; Rats; Rats, Wistar; Stereotyped Behavior | 2001 |
Oral dyskinesias and morphological changes in rat striatum during long-term haloperidol administration.
Topics: Animals; Antipsychotic Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Haloperidol; Immunohistochemistry; Mastication; Microscopy, Electron; Rats; Rats, Sprague-Dawley; Synapses | 2001 |
The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches.
Topics: Anticonvulsants; Antiparkinson Agents; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Glutamic Acid; Humans; Levodopa; Parkinson Disease; Riluzole | 2001 |